Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Osilodrostat

EU orphan designation number: EU/3/14/1345   
Active ingredient: Osilodrostat
Indication: Treatment of Cushing's syndrome
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
17/10/2014 Orphan designation EMA/OD/099/14 (2014)7644 of 15/10/2014